ABSTRACT
Inflammation following neonatal infection is a dominant cause of childhood hydrocephalus in the developing world. Understanding this complex inflammatory response is critical for the development of preventive therapies. In 100 African hydrocephalic infants ≤3 months of age, with and without a history of infection, we elucidated the biological pathways that account for this inflammatory response. We integrated proteomics and RNA sequencing in cerebrospinal fluid, identifying gene pathways involving neutrophil, interleukin (4, 12, and 13) and interferon activity associated with this condition. These findings are required to develop strategies to reduce the risk of hydrocephalus during treatment of infection.
Competing Interest Statement
Dr. Limbrick receives research funds and/or research equipment for unrelated projects from Medtronic, Inc. and Microbot Medical, Inc. Dr. Limbrick has received philanthropic equipment contributions for humanitarian relief work from Karl Storz, Inc. and Aesculap, Inc. The authors have no personal, financial, or institutional interest in any of the materials, or devices described in this article.
Funding Statement
We received funding from the National Institutes of Health Directors Pioneer Award 5DP1HD086071-05 to SJS, Hydrocephalus Association 2018 Discovery Science Award to RRT, and Vanier Canada Graduate Scholarship 396212 to AMI. None of the organizations listed had any role in the study design, data collection, data analysis, data interpretation, writing or decision to submit the report for publication. None of the authors or their institutions at any time received payment or services from a third party for any aspect of the submitted work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics oversight was provided by the CURE Children's Hospital of Uganda Institutional Review Board (IRB), Mbarara University of Science and Technology Research Ethics Committee, the Ugandan National Council on Science and Technology, and the Pennsylvania State University IRB.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All relevant data for this manuscript have been included in the methodology and results
